Novartis Ag (NVS) Non-Current Deferred Tax Liability (2009 - 2026)

Novartis Ag (NVS) has 12 years of Non-Current Deferred Tax Liability data on file, last reported at -$2.5 billion in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to -$2.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.5 billion (changed N/A YoY) and the FY2025 annual result came in at $3.4 billion, up 525.16% from the prior year.
• Non-Current Deferred Tax Liability fell to -$2.5 billion in Q1 2026 per NVS's latest filing, from $3.4 billion in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $3.4 billion in Q4 2025, with the low at -$2.5 billion in Q1 2026.
• Average Non-Current Deferred Tax Liability over 5 years is $651.8 million, with a median of -$276.0 million recorded in 2022.
• Year-over-year, Non-Current Deferred Tax Liability slumped 877.42% in 2022 and jumped 933.66% in 2023.
• Novartis Ag's Non-Current Deferred Tax Liability stood at $2.7 billion in 2022, then sank by 117.65% to -$474.0 million in 2023, then slumped by 68.57% to -$799.0 million in 2024, then jumped by 525.16% to $3.4 billion in 2025, then tumbled by 173.59% to -$2.5 billion in 2026.
• Business Quant data shows NVS's Non-Current Deferred Tax Liability at -$2.5 billion in Q1 2026, $3.4 billion in Q4 2025, and $2.3 billion in Q2 2025.